Literature DB >> 20874050

Long term hearing degeneration after platinum-based chemotherapy in childhood.

Einar J Einarsson1, Hannes Petersen, Thomas Wiebe, Per A Fransson, Jan Grenner, Mås Magnusson, Christer Moëll.   

Abstract

The aim of this study was to investigate long-term development of hearing in subjects who had received platinum-based chemotherapy in childhood or adolescence. Another aim was to assess the self-reported hearing loss handicap and compare it to audiometric measurements. Medical records from individuals diagnosed with childhood cancer and treated with platinum-based chemotherapy between 1985 and 2000 at the University Hospital in Lund Sweden were reviewed retrospectively. Fifteen subjects, who fulfilled the eligibility criteria set for the study, underwent a thorough audiometric evaluation. The results show that the hearing loss, in subjects with ototoxicity had increased after the end of treatment, to include also the lower frequencies. The largest deterioration in hearing thresholds, up to 55 dB HL, was found at frequencies above 2 kHz. The findings also reveal that the subjects have a considerably greater hearing loss handicap and disability than would be expected from the results of the audiometric evaluations. The conclusion of this study is that children and adolescence treated with platinum-based chemotherapy should have regular audiometric follow-up examinations, also many years after the end of treatment. Furthermore, assessments of self-reported hearing disability should be made during and after chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20874050     DOI: 10.3109/14992027.2010.485595

Source DB:  PubMed          Journal:  Int J Audiol        ISSN: 1499-2027            Impact factor:   2.117


  15 in total

1.  Cisplatin-induced ototoxicity and the role of pharmacogenetic testing.

Authors:  Lauren E Wyatt; Mary Jayne Kennedy
Journal:  J Pediatr Pharmacol Ther       Date:  2012-10

2.  Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.

Authors:  James G Gurney; Johnnie K Bass; Arzu Onar-Thomas; Jie Huang; Murali Chintagumpala; Eric Bouffet; Tim Hassall; Sridharan Gururangan; John A Heath; Stewart Kellie; Richard Cohn; Michael J Fisher; Atmaram Pai Panandiker; Thomas E Merchant; Ashok Srinivasan; Cynthia Wetmore; Ibrahim Qaddoumi; Clinton F Stewart; Gregory T Armstrong; Alberto Broniscer; Amar Gajjar
Journal:  Neuro Oncol       Date:  2014-01-10       Impact factor: 12.300

3.  An optimized, clinically relevant mouse model of cisplatin-induced ototoxicity.

Authors:  K Fernandez; T Wafa; T S Fitzgerald; L L Cunningham
Journal:  Hear Res       Date:  2019-02-22       Impact factor: 3.208

4.  Long-term auditory follow-up in the management of pediatric platinum-induced ototoxicity.

Authors:  Anna Rita Fetoni; Francesca Brigato; Eugenio De Corso; Daniela Lucidi; Bruno Sergi; Emanuele Scarano; Jacopo Galli; Antonio Ruggiero
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-01-13       Impact factor: 3.236

Review 5.  Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention.

Authors:  Jochen Schacht; Andra E Talaska; Leonard P Rybak
Journal:  Anat Rec (Hoboken)       Date:  2012-10-08       Impact factor: 2.064

6.  Early Physiological and Cellular Indicators of Cisplatin-Induced Ototoxicity.

Authors:  Yingying Chen; Eric C Bielefeld; Jeffrey G Mellott; Weijie Wang; Amir M Mafi; Ebenezer N Yamoah; Jianxin Bao
Journal:  J Assoc Res Otolaryngol       Date:  2021-01-07

Review 7.  Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium.

Authors:  Eva Clemens; Marry M van den Heuvel-Eibrink; Renée L Mulder; Leontien C M Kremer; Melissa M Hudson; Roderick Skinner; Louis S Constine; Johnnie K Bass; Claudia E Kuehni; Thorsten Langer; Elvira C van Dalen; Edith Bardi; Nicolas-Xavier Bonne; Penelope R Brock; Beth Brooks; Bruce Carleton; Eric Caron; Kay W Chang; Karen Johnston; Kristin Knight; Paul C Nathan; Etan Orgel; Pinki K Prasad; Jan Rottenberg; Katrin Scheinemann; Andrica C H de Vries; Thomas Walwyn; Annette Weiss; Antoinette Am Zehnhoff-Dinnesen; Richard J Cohn; Wendy Landier
Journal:  Lancet Oncol       Date:  2019-01       Impact factor: 54.433

Review 8.  Supporting Cells and Their Potential Roles in Cisplatin-Induced Ototoxicity.

Authors:  Sofia Waissbluth; Juan Cristóbal Maass; Helmuth A Sanchez; Agustín D Martínez
Journal:  Front Neurosci       Date:  2022-04-27       Impact factor: 4.677

9.  Decreased postural control in adult survivors of childhood cancer treated with chemotherapy.

Authors:  Einar-Jón Einarsson; Mitesh Patel; Hannes Petersen; Thomas Wiebe; Per-Anders Fransson; Måns Magnusson; Christian Moëll
Journal:  Sci Rep       Date:  2016-11-10       Impact factor: 4.379

10.  Prospective evaluation of cisplatin- and carboplatin-mediated ototoxicity in paediatric and adult soft tissue and osteosarcoma patients.

Authors:  Alexandra Nitz; Evangelos Kontopantelis; Stefan Bielack; Ewa Koscielniak; Thomas Klingebiel; Thorsten Langer; Marios Paulides
Journal:  Oncol Lett       Date:  2012-10-25       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.